As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months ...

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...

Margin expansion at Express Scripts, Caremark and Optum Rx increased by $336 million between 2017 and 2021, officials say.

Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs, ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

Pharmacy Benefit Managers (PBM) sit in the center of our prescription drug system, coordinating between insurance companies, ...

The FTC prioritized testimony from drugmakers and pharmacies, industries that benefit from weakening PBMs, said David Whitrap, vice president of external affairs at CVS Health. Need a break?

The FTC’s investigation into PBM practices began in 2022. Last summer, the agency released a scathing interim report on the industry. It detailed how increasing concentration enabled the three ...

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...